News
Sixteen Years Clear, Then it Came Back: A Husband’s Reckoning with Cancer, Faith, and the Ordinary Courage of Carrying On
For sixteen years, cancer became something we spoke about in the past tense. My wife, Lynn, had survived a rare smooth-muscle cancer (leiomyosarcoma) after two operations in 2009. Year after year the scans came back clear. Gradually, we stopped living…
In Memoriam: Dr Mary Buchanan (1929–2026)
The European cancer community has lost one of its most influential voices for breast cancer advocacy. Dr. Mary Buchanan—physician, advocate, and one of the founding figures of Europa Donna – The European Breast Cancer Coalition—passed away on 18 June 2026.…
Oncology Couch: Questions, Answers, and the Space in Between
To patients and oncologists alike: Are there questions living inside you that you have not been asking out loud? Could it be that you do not even know what questions to ask? Are there answers you have arrived at privately…
CancerWorld #118 (August 2026)
We often describe progress in oncology through the language of discovery. Scientific breakthroughs. Technological innovation. Deeper biological insight. These advances have transformed medicine, helping millions of people live longer and better than ever before. Yet alongside every scientific breakthrough, a…
Could GLP-1 Drugs Slow Cancer Spread? New Study Offers Encouraging Clues
Treatment with GLP-1 receptor agonists (GLP-1RAs) was associated with a significantly lower risk of progression to metastatic disease in non–small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), and hepatocellular carcinoma (HCC). The study, presented at the 2026 American…
When RAS Becomes Treatable: Eileen O’Reilly on daraxonrasib in Pancreatic Cancer
Daraxonrasib nearly doubled median survival in previously treated metastatic pancreatic cancer. For Dr Eileen O’Reilly, the result is not simply a remarkable curve on a conference screen, but the beginning of a new way to think about a disease long…
Daraxonrasib: A Turning Point for Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…
CancerWorld #117 (July 2026)
We often describe progress in oncology through the language of innovation. New drugs. New technologies. New discoveries. Yet scientific breakthroughs rarely change cancer care on their own. They require people willing to pursue difficult ideas, build institutions, challenge accepted thinking,…
The Ovation and the Asterisk
Five trials, five cancers, and what the ASCO 2026 plenary really promised patients ASCO 2026’s plenary delivered five real advances across five cancers, and a standing ovation that pulled a hall full of oncologists to their feet. The harder question…
Between Theory and Bedside: What Early Palliative Care in Singapore Reveals About Cancer, Care, and the Limits of Knowledge
On paper, cancer care can be mapped, measured, and modelled. In practice, it is far less contained. For Charis Ng, a trainee health psychologist and PhD student, that gap between theory and lived reality became impossible to ignore during her…